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Abstract
Ovarian carcinoma is the leading cause of death among gynecologic cancers. Although transformation of the outer
ovarian epithelium was linked with ovulation, the disease is significantly more prevalent and severe in postmeno-
pausal women. We postulated that menopause could augment ovarian cancer progression through the effects of
gonadotropins on multifocal seeding to the mesothelial layer lining the peritoneum. This seeding is mediated by
integrins as well as by CD44 interaction with hyaluronan (HA). Here, we report the effect of gonadotropins on HA
synthesis and degradation and on peritoneal adhesion. A significant concentration- and time-dependent induction
in expression levels of HA synthases (HASs) and hyaluronidases (Hyals) was observed in vitro on stimulation of
human epithelial ovarian carcinoma cells by gonadotropins. Hormonal regulation of HA-mediated adhesion was
manifested in vivo as well, by fluorescence microscopy of stained MLS multicellular tumor spheroids. The number
of spheroids adhered to the mesothelium of ovariectomized CD-1 nude mice 9.5 hours after intraperitoneal insertion
was significantly higher than in nonovariectomized mice. Inhibition of HA synthesis by 6-diazo-5-oxo-1-norleucine
(DON) both in spheroids and ovariectomized mice significantly reduced the number of adhered spheroids. Thus,
the change in the hormonal environment during menopause assists in HA-dependent adherence of ovarian cancer
spheroids onto the peritoneum. However, HA is antiangiogenic and it can significantly suppress tumor progression.
Accordingly, angiogenesis of the adhered spheroids was significantly elevated in DON-treated tumors. These re-
sults can explain the selective pressure that can lead to simultaneously increased tumor expression of both HASs
and Hyals.
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Introduction
Throughout menopause, changes in the hormonal milieu could pro-
vide important regulatory switches for angiogenesis and tumor progres-
sion. These hormonal changes include elevated levels of luteinizing
hormone (LH) and follicular-stimulating hormone (FSH) [1] and re-
duced levels of estrogen and progesterone, which can affect progression
of ovarian carcinoma directly and indirectly through their influence on
expression of proangiogenic and antiangiogenic factors. Among these
changes, the best studied is the effect of the gonadotropin hormones,
LH and FSH, which have been shown to be involved in human epi-
thelial ovarian carcinoma. On the one hand, exposure of high hormone
levels during menopause or during fertility treatments raised the occur-
rence of the disease [2–4], and conversely, oral contraceptives, hyster-
ectomy, multiple pregnancies, breast-feeding, and estrogen replacement
therapy, which all lessen exposure to gonadotropins, resulted in reduced
risk [3,5,6]. Ovarian cancer cells were reported to express receptors for
these hormones [7,8] and show a direct response in proliferation rate
[9]. Two additional indirect effects have been reported by us. First,
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elevated expression of vascular endothelial growth factor (VEGF ) [10],
which promotes angiogenesis, and second, hormonal-induced expres-
sion of integrins and the hyaluronan (HA) receptor CD44 [11], which
affects cell adhesion, were induced by LH and FSH. Subsequent stud-
ies confirmed elevated expression of VEGF in clinical samples of ovar-
ian carcinomas in addition to dose-dependent VEGF induction by the
gonadotropins LH and FSH [12]. These studies suggest that suppres-
sion of gonadotropin levels may negatively affect angiogenesis, cell ad-
hesion, and metastasis, resulting in protection from ovarian cancer, yet
the role that gonadotropins play in ovarian tumorigenesis remains to
be fully elucidated.
An important component of the extracellular matrix (ECM) with
respect to ovarian cancer progression is HA [13–15]. HA is a linear,
negatively charged, high–molecular weight glycosaminoglycan poly-
mer constructed from repeating [-D-glucoronic acid-β1,3-N -acetyl-
D-glucosamine-β1,4-]n units. High–molecular weight HA inhibits
angiogenesis during development [16], reproduction [17], and in tu-
mors [18], whereas its products of degradation are known to stimulate
endothelial cell proliferation and promote neovascularization [19].
Within the tumor environment, the production of high–molecular
weight HA is thought to provide a hydrated matrix which forces gaps
in the ECM, facilitating tumor cell migration and metastasis.
Ovarian carcinoma cells often grow as multicellular spheroids in
the ascitic fluid. Metastasis in ovarian cancer is initiated by multifocal
seeding of cells or small spheroids onto the mesothelial layer lining
the peritoneum [20,21]. Those cells recognize and adhere onto HA
produced by the mesothelial cells through the HA receptor CD44, in
addition to collagen adhesion through the expression of integrins [21].
After collagen binding, the spheroids disintegrate, and HA induces tu-
mor cell motility [13]. Previous studies have revealed a mechanism
where rapid HA-mediated attachment is subsequently replaced by sta-
ble integrin-mediated contacts [22,23]. In ovarian cancer, the expres-
sion of CD44 was linked with better prognosis [24], and yet, as shown
previously by us, was induced by gonadotropin stimulation alongside
with increased adhesion of the cancer cells onto HA [11].
Ovarian cancer cells manage to overcome the antiangiogenic activ-
ity of high–molecular weight HA by the expression of hyaluronidase
(Hyal), which degrades HA into proangiogenic fragments. The hu-
man and mouse genomes include a family of six Hyals that differ in
their tissue expression and in the size of fragments they generate [25].
The main Hyals studied are Hyal1 and Hyal2. Hyal1, which is the
most abundant plasma and urine Hyal, is defined by tumor sup-
pressor activity [26] and breaks HA down to small fragments. Hyal2
generates intermediate HA fragments of roughly 20 kDa, which are
proangiogenic and are found to have oncogenic activity [25]. Hence,
Hyal expression can promote or suppress tumor progression depend-
ing on the circumstances of action [27]. Using a self-quenched “smart”
magnetic resonance imaging reporter probe, we previously demon-
strated the secretion of active Hyal by ovarian carcinoma cells both
in vitro and in vivo, thus allowing the tumor to convert its micro-
environment to be proangiogenic [28].
HA is synthesized by a multi-isoform family of transmembrane
glycosyltransferases termed the HA synthase (HAS) [29]. Three dis-
tinct yet highly conserved eukaryotic HAS isoforms have been iden-
tified and termed HAS1, HAS2, and HAS3. HASs were shown to be
associated with the progression of various cancers. Recently, it has
been shown that HAS1 regulates bladder cancer growth and progres-
sion by modulating HA synthesis and HA receptor levels [30]. Ele-
vated HAS1 expression and/or intronic gene splicing correlates with
poor prognosis in human colon cancer, ovarian cancer, and multiple
myelomas [31–33]. Expression levels of HA and HAS2, as well as the
rate of HA synthesis, were shown to be increased in highly metastatic
breast carcinoma cells [34]. Temporary inhibition of HA synthesis in
the rat ovary was performed using the metabolic inhibitor DON
[17]. Targeted HAS2 suppression in mouse cumulus cell–oocyte
complexes was carried out by adenovirus-mediated short-hairpin
RNA expression [35].
The goal of this study was to investigate the effect of LH and FSH
on HA synthesis and degradation with respect to the peritoneal ad-
hesion and angiogenesis of ovarian carcinoma. We report here that
gonadotropins augment the expression of HAS and Hyal in vitro. Ac-
cordingly, elevation of gonadotropin levels in vivo by ovariectomy
(OVX) enhanced the ability of ovarian carcinoma multicellular
spheroids to adhere onto the peritoneum. Inhibition of HA synthesis
was sufficient for overcoming the enhanced tumor metastatic implan-
tation induced by OVX. However, angiogenesis was potently sup-
pressed by HA and was significantly augmented by suppression of
HA synthesis. Thus, the changes in the hormonal milieu that accom-
pany menopause can lead to increased metastatic implantation of
ovarian cancer cells or spheroids on the mesothelial layer lining the
peritoneum, whereas degradation of HA was important for tumor
angiogenesis and further progression. The hormonal effect on HA
metabolism and on the adhesion process, and the impact of HA on
tumor angiogenesis, may help shed light on the clinical change in ag-
gressiveness of ovarian cancer in postmenopausal women and further
underscore the complexity of HA as a possible target for therapy.
Materials and Methods
Monolayer and Multicellular Spheroid Culture
MLS human epithelial ovarian carcinoma cells were a kind gift
from Prof. Robert Sutherland [36]. ES2 cells were kindly provided
by Prof. Hauptmann Charite. MLS spheroids were cultured in α-
minimum essential medium supplemented with 10% fetal calf serum
(Biological Industries, Beit Haemek, Israel), 1% L-glutamine (Biolog-
ical Industries), and antibiotics: 50 U/ml penicillin (Biological Indus-
tries) and 50 μg/ml streptomycin (Biological Industries). Spheroids
(0.4-1 mm in diameter) were initiated by plating cells from a confluent
culture onto agar-coated plates. Seventy-two hours later, the spheroids
were transferred to a 500-ml spinner flask (Belco, Vineland, NJ) at
a spinning rate of 80 rpm. The medium was changed every 48 hours
for 1 month, and a mixture of 95% air and 5% carbon dioxide was
blown over the medium for 5 minutes [37].
Hormonal Stimulation
Human LH and human FSH were a kind gift from Dr. Fortune
Kohen. Hormones were dissolved in phosphate-buffered saline and
stored at −80°C at a concentration of 1 mg/ml. After 24 hours of
culture in serum-free medium, MLS and ES2 human epithelial ovar-
ian carcinoma cell lines were treated with either LH (1 ng/ml) or FSH
(1 ng/ml) for varying periods (6, 12, 18, 24, and 48 hours for the
MLS cells, and 6, 12, 18, 24, 30, and 36 hours for the ES2 cells).
RNA Extraction, Reverse Transcription, and Polymerase
Chain Reaction
After hormonal stimulation, total RNA was isolated from the ovar-
ian carcinoma cell lines using TRI-REAGENT (Molecular Research
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Center, Inc., Cincinnati, OH) according to the manufacturer’s instruc-
tions and was reverse-transcribed in 20-μl (3 μg) volumes using RNase
H reverse transcriptase (Super-Script II; Invitrogen Life Technologies,
Inc., Carlsbad, CA) with 180 pmol of hexamer randomprimer. Aliquots
(2 μl) of the reverse transcription products were used for polymer-
ase chain reaction (PCR). Semiquantitative PCRs were carried out using
primers of interest to determine the transcription level of human HAS1
(NM_001523) (5′-ACTGTACTTTTGGGGATGACC and 5′-CAG-
CAGAGGGACGTAGTTAG), human HAS2 (NM_005328) (5′-
CCCAGCCTCATCTGTGGAG and 5′-ACCCCGGTAGAA-
GAGCTGG), human HAS3 (NM_005329) (5′-TCGGTGGC-
ACTGTGCATTG and 5′-CTACTTGGGGATCCTCCTG), human
Hyal1 (NM_007312.3) (5′-CTATGGCTTCCCTGACTGCT
and 5′-GGCAGAAAGTGGTTTGTCGT), and human Hyal2
(NM_033158) (5′-ATGAGTTTGAGTTCGCAGCA and 5′-AG-
CAGCCGTGTCAGGTAATC). The transcription level of GAPDH
(5′-CGGAGTCAACGGATTTGGTCGTAT and 5′-AGCCTTCTC-
CATGGTGGTGAAGAC) was determined as well and used for cali-
bration of the results. PCR parameters: 2 minutes at 94°C, 5 cycles of
30 seconds at 94°C, 60 seconds at 55°C, 90 seconds at 72°C, followed
by 25 cycles (or 19, 21, 23, and 25 cycles for the semiquantitative
PCR) of 30 seconds at 4°C, 60 seconds at 60°C, 90 seconds at 72°C,
and 10 minutes at 72°C. PCR products were analyzed on agarose gel by
measuring their intensity levels.
Animal Protocols
All animal procedures were approved by the Institutional Animal
Care and Use Committee.
Ovariectomy. Female CD-1 nude mice (6 weeks old, 20-g body
weight) were anesthetized with ketamine HCl (75 μg/g, i.p.) and xy-
lazine HCl (3 μg/g). Both ovaries were removed through 4-mm in-
cisions, and the mice were allowed to fully recover for 2 to 3 weeks.
Spheroid i.p. insertion. One hundred microliters containing ap-
proximately 350 fluorescently stained spheroids (0.7 mm in diameter)
per mouse were i.p. inserted into OVX CD-1 nude mice. At 5, 7, 9.5,
24, and 96 hours later, mice were killed, equal sizes of peritonea were
excised, extensively washed in PBS, and spread out on slides to detect
spheroid adhesion by low-resolution fluorescence imaging (IVIS 100;
Xenogen, Alameda, CA) and fluorescence microscopy (Axio; Zeiss,
Yena, Germany).
Fluorescent Staining of MLS Spheroids
4-Di-10-Asp, a lipophilic tracer, was dissolved in ethanol at 1 mg/ml.
Spheroids were washed five times in sterile PBS and then incubated
at 37°C with 4-Di-10-Asp (7.5 μg/ml) for 1 hour at 90 rpm. Excess
dye was removed by washing the cells with sterile PBS.
Di-D, a lipophilic tracer, was dissolved in ethanol to the concentra-
tion of 2 mg/ml. Spheroids were washed five times in sterile PBS and
then incubated at 37°C with Di-D (7.5 μg/ml) for 1 hour at 90 rpm.
Excess dye was removed by washing the cells with culture medium.
Histology
Peritoneum was fixed in Carnoy solution (ethanol-chloroform-acetic
acid, 6:3:1). Histologic sections (5 μm) were stained with hematoxylin
and eosin (H&E).
After fixation in 4% paraformaldehyde (PFA), tissues (OVX + DON
n = 3, OVX − DON n = 3, non–OVX + DON n = 3, non–OVX −
DON n = 3) were embedded in paraffin and sectioned at 4-μm thick-
ness. Sections were deparaffinized for 5 minutes with xylene, ethanol
hydrated, antigen retrieved, PBS washed, and blocked in 1% horse se-
rum. Staining was carried out using anti–CD34 antibody (Cedarlane
Laboratories, Burlington, NC). Detection of the anti–CD34 anti-
body was performed by using a biotin-SP–conjugated anti–rat anti-
body ( Jackson ImmunoResearch Laboratories, West Grove, PA) and
Cy3-conjugated streptavidin ( Jackson ImmunoResearch Laboratories).
Staining was detected using a fluorescent microscope (Zeiss Axioscope II;
Simple PCI software).
In Situ Hybridization
For preparation of HAS2 mRNA probes, RT-PCR was carried out us-
ing the following pairs of primers: 5′-GGGCACATCAGGAAG-
GAAAAC and 5′-ACAGCGTCAAAAGCATGACC. After cloning the
fragments using the pGEM-T Easy Vector System (Promega, Madison,
WI), digoxigenin-labeled riboprobes were prepared by in vitro transcrip-
tion using the DIG RNA Labeling Kit (Roche, Basel, Switzerland).
Tissues fixed in 4% PFA were embedded in paraffin and serially
sectioned at 7-μm thickness (OVX n = 3, non-OVX n = 3). Sections
were deparaffinized, hydrated, digested with proteinase K (Sigma
Chemical Co., St. Louis, MO), rinsed with TBS, incubated in 4%
PFA, dehydrated, and then incubated with a hybridization mixture
for 45 minutes at 55°C. Hybridization with the specific probes was
carried out overnight at 63°C using 1-μg/ml riboprobes. After the
hybridization procedure, sections were washed with SSC, TBS, and
then blocked with 1% BSA. For detection of the digoxigenin-labeled
riboprobes, sections were incubated with antidigoxigenin alkaline
phosphatase (Roche) and stained with NBT/BCIP (Roche). Staining
was detected using an E800 microscope and digital camera DXM
1200 (Nikon, Tokyo, Japan).
In Vitro and In Vivo Inhibition of HA Synthesis
Spheroids were transferred into a 250-ml spinner flask (Belco),
and 6-diazo-5-oxo-1-norleucine (DON; Sigma) was added (5 μg/ml)
every 24 hours for 2 days. OVX CD-1 nude mice were i.p. injected
with DON (7.5-μg/g body weight) every 24 hours for 2 days as well.
After 48 hours, 100 μl containing approximately 350 DON-treated
spheroids (0.7 mm in diameter) per mouse was stained with 4-Di-
10-Asp and i.p. inserted into the DON-treated mice. After spheroid
insertion, mice were i.p. injected with DON (7.5 μg/g) once more.
At 9.5 hours later, mice were killed, and equal sizes of peritoneum tis-
sues were excised, extensively washed, and spread on slides for further
detection of spheroid adhesion by fluorescence imaging and fluores-
cence microscopy.
Fluorescent Staining of Blood Vessels
Dextran–fluorescein isothiocyanate (FITC; Sigma) or BSA-ROX at
the final concentration of 10 mg/ml was i.v. injected (200 μl per
mouse) through the tail vein 4 minutes before mouse sacrifice. Equal
sizes of peritonea were excised, extensively washed in PBS, and spread
out on slides to visualize adhered spheroids and blood vessels by fluo-
rescence microscopy (Axio; Zeiss). Blood vessel density and diameter
was analyzed after CD34 staining using Image J (National Institutes of
Health; http://rsb.info.nih.gov/ij).
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Results
HA Synthesis and Degradation in Ovarian Carcinoma Cells
Are Hormonally Regulated
A number of human epithelial ovarian carcinoma cell lines were
evaluated for the expression of the HAS1, HAS2, and HAS3 genes
(Table 1). Whereas none of the cell lines expressed the HAS1 gene,
the MLS and ES2 cell lines were shown to express both HAS2 and
HAS3. Because previous studies in our laboratory investigated the
expression of VEGF, CD44, and αV-integrin after LH and FSH stim-
ulation in MLS cells, we therefore selected the MLS cell line for the
analysis of HAS2 and HAS3 expression levels. MLS cells were treated
with either LH or FSH (1 ng/ml) and were analyzed at varying time
points (6, 12, 18, 24, and 48 hours). Total RNA was extracted from
the cells and reversed-transcribed. Semiquantitative PCR was per-
formed to determine the linear cycle in which HAS2 and HAS3 are
detected. Induction levels of HAS2 and HAS3 were set by PCR of
22 and 23 cycles, respectively. MLS cells stimulated with FSH showed
a significant induction in expression levels of both HAS2 and HAS3
24 hours after induction (n = 4, *P < .05, two-tailed, equal-variance
t test; Figure 1C ). Stimulation with LH caused a significant induc-
tion in HAS2 expression levels 48 hours after induction (n = 4,
*P < .05, two-tailed, equal-variance t test) and in HAS3 expression lev-
els 24 hours after hormonal treatment (n = 4, *P < .05, two-tailed,
equal-variance t test; Figure 1D). To verify that gonadotropins induce
HAS expression not only in MLS cells, ES2 cells were treated with
either LH or FSH (1 ng/ml) as well and were analyzed at varying time
points (6, 12, 18, 24, 30, and 36 hours) for HAS2 and HAS3 ex-
pression levels. FSH treatment significantly induced HAS3 expression
6 and 18 hours after induction (n = 3, *P < .05, two-tailed, equal-
variance t test; Figure 1E), and LH stimulation significantly induced
HAS3 expression levels 6, 12, and 18 hours after induction (n = 3,
*P < .05, two-tailed, equal-variance t test; Figure 1F). The HAS2 gene
was not induced after FSH treatment; nevertheless, enhanced expres-
sion was viewed after LH stimulation although not significant.
MLS cells were shown to express the Hyal1 and Hyal2 genes as well.
Semiquantitative PCR was performed to determine the linear cycle in
which Hyal1 and Hyal2 are detected. Induction levels of Hyal1 and
Hyal2 were set by PCR of 24 and 22 cycles, respectively. MLS cells
stimulated with FSH demonstrated a significant induction in expres-
sion levels of Hyal1 6, 24, and 48 hours after induction (n = 3, *P <
.05, two-tailed, equal-variance t test), whereas no significant induction
or reduction was detected for Hyal2 expression levels (Figure 1G ).
MLS cells stimulated with LH exhibited a significant induction in ex-
pression levels of both Hyal1 and Hyal2 24 hours after hormonal in-
duction (n = 3, *P < .05, two-tailed, equal-variance t test; Figure 1H ).
LH and FSH Elevation Augment Spheroid Adhesion In Vivo
Ovarian cancer metastasis initiates by multifocal seeding of cells or
spheroids on the mesothelial layer lining the peritoneum, by binding
of cell surface CD44 onto HA produced by the mesothelium [20,21].
Because HAS2 and HAS3 expression in the MLS cell line is hormon-
ally regulated in vitro, we set out to study the hormonal regulation of
HA-mediated adhesion in vivo. OVX mice were used here as a model
for the hormonal environment associated with ovarian failure during
menopause. MLS cells cultured as multicellular tumor spheroids the
size of 0.7 mm, and prelabeled with the vital stain 4-Di-10-Asp, were
i.p. inserted into OVX CD-1 nude mice (n = 4) as well as into non-
OVX mice that served as a control (n = 3). Mice were killed 5, 7, and
9.5 hours later, and their peritonea were equally excised and exten-
sively washed for spheroid adhesion detection by fluorescence imaging
(Figure 2A). No ascetic fluid accumulation was observed. Peritoneum
tissue from naive non-OVX mice, which was not i.p. inserted with
fluorescent spheroids, was added as reference for autofluorescence.
Although the OVX mice displayed increasing signal intensity and
spread as the time of adhesion progressed, the non-OVX mice scarcely
demonstrated any fluorescence, regardless of the adhesion time (Fig-
ure 2A) demonstrating a clear differentiation between the peritonea
of OVX (n = 4) and non-OVXmice (n = 3), where adhesion is elevated
in the OVX mice. The peritoneum tissues were further visualized
by fluorescence microscopy for quantification purposes (Figure 2B).
The peritoneum in non-OVX mice contained only a small number
of adhered spheroids, which were small and on the verge of degrada-
tion after 9.5 hours. In OVX mice, the peritoneum contained many
adhered spheroids, which were larger and were more intergraded in
the tissue as the time progressed (Figure 2B). The number of small
(≤0.1 mm), large (≥0.1 mm), and bulk aggregates (>1 spheroid) of
spheroids was quantified, displaying a significantly greater amount
of small, large, and bulks of spheroids detected on the mesothelium
of OVX mice compared with non-OVX mice 9.5 hours after insertion
(P < .05; Figure 2C).
Histologic H&E–stained sections showed extensive adherence of
spheroids onto the peritoneal tissue of OVX mice 5 hours after in-
sertion (Figure 2B). Seven hours after insertion, invasion into the tu-
mor is beginning to develop, and 2.5 hours later, the spheroid had
further invaded the tissue (Figure 2B). Here, OVX is found to pro-
mote the adhesion process by increasing spheroid adhesion and sub-
sequent invasion in the peritoneal cavity.
Tumor and Muscle Expression of HAS2 Is Induced in
OVX Mice
MLS cells were cultured as multicellular tumor spheroids, prela-
beled with the vital stain 4-Di-10-Asp, i.p. inserted into OVX CD-1
nude mice (n = 3) as well as into non-OVX mice that served as a
control (n = 3) and killed 4 days later. In situ hybridization with a
HAS2-specific probe was carried out on histologic sections derived
from 4-day adhered MLS spheroids in OVX versus non-OVX mice.
Because both the mouse and human HAS2 genes are 90% homo-
logues within their coding region, we designed one HAS2 probe that
can detect the HAS2 gene of both species. The staining indicated an
increase in the HAS2 mRNA levels both in the tumor and in the peri-
toneal muscle in the OVX group compared with the control (Figure 3).
Therefore, OVX induces the expression of HAS2 mRNA, thus sup-
porting the in vitro results seen in Figure 1 where LH and FSH in-
duced the expression of HAS2.
Inhibition of HA Synthesis Reduces Spheroid Adhesion In Vivo
The hormonal regulation of HA synthesis on the adhesion process
was evaluated in vivo. For this purpose, HAS activity was suppressed
Table 1. Expression of HAS by Ovarian Carcinoma Cells.
Cell Line HAS1 HAS2 HAS3
MLS − + +
OC-238 − − −
ES-2 − + +
A-27/80 − − +
OVCAR − − +
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Figure 1. Gonadotropin stimulation regulates HA synthesis and degradation in ovarian carcinoma.MLS and ES2 cells were treatedwith hLH
or hFSH (1 ng/ml) after 6, 12, 18, 24, and 48 hours or after 6, 12, 18, 24, 30, and 36 hours respectively. Cells were harvested, and total RNA
was isolated and reverse-transcribed. HAS2, HAS3, Hyal1, and Hyal2 levels were determined by semiquantitative PCR. Band intensity
was normalized to GAPDH. (A) Representative agarose gels of HAS2, HAS3, and GAPDH expression in MLS cells after FSH stimulation.
(B) Representative agarose gels of HAS2, HAS3, and GAPDH expression in MLS cells after LH stimulation. (C) hFSH’s effects on HAS2
and HAS3 expression levels at 1 ng/ml in MLS cells (error bars, SE; *P < .05, two-tailed, equal-variance t test). (D) hLH’s effects on HAS2
andHAS3 expression levels at 1 ng/ml in MLS cells (error bars, SE; *P< .05, two-tailed, equal-variance t test). (E) hFSH’s effect onHAS2 and
HAS3 expression levels at 1 ng/ml in ES2 cells (error bars, SE; *P< .05, two-tailed, equal-variance t test). (F) hLH’s effect onHAS2 and HAS3
expression levels at 1 ng/ml in ES2 cells (error bars, SE; *P < .05, two-tailed, equal-variance t test). (G) hFSH’s effect on Hyal1 and Hyal2
expression levels at 1 ng/ml in MLS cells (error bars, SE; *P < .05, two-tailed, equal-variance t test). (H) hLH’s effect on Hyal1 and Hyal2 ex-
pression levels at 1 ng/ml in MLS cells (error bars, SE; *P < .05, two-tailed, equal-variance t test). All t tests were compared with time 0.
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both in the spheroids and in the OVX mice by treatment with DON,
a metabolic inhibitor of glucosamine synthesis. The average size of
DON-treated spheroids (0.32 ± 0.15 mm 2 days after DON treat-
ment) was slightly but significantly larger than spheroids that were
not treated with DON (0.23 ± 0.07 mm; data not shown). MLS cells
cultured as spheroids (0.7 mm in diameter), and prelabeled with the
vital stain 4-Di-10-Asp, were treated with DON and i.p. inserted into
CD-1 nude OVX mice treated with DON as well (n = 5). Control
OVX mice, not treated with DON, were inoculated with nontreated
spheroids (n = 3). Mice were killed 9.5 hours later, and their peritonea
were equally excised and extensively washed to visualize spheroid ad-
hesion by fluorescence imaging and microscopy (Figure 4). No ascetic
fluid accumulation was observed. In contrast to the peritoneum of un-
treated mice showing multiple adhered spheroids, DON-treated spher-
oids scarcely showed any adhesion, demonstrating the role of HA on
the adhesion process (Figure 4A). The whole tissue fluorescence mi-
croscopy images illustrated a wide spread of fluorescence throughout
the DON-treated peritoneum in comparison to the control peritoneum
where the fluorescence is very faint and decreased in its spread (Fig-
ure 4A). The number of small (≤0.1 mm), large (≥0.1 mm), and bulks
(>1 spheroid) of spheroids was quantified. On HA synthesis inhibi-
tion by DON both in spheroids and OVX mice, the number of large
Figure 2. Peritoneal spheroid adhesion is elevated in OVX mice.
Spheroids of 0.4 to 0.5 mm were stained with 4-Di-10-Asp and i.p.
inserted into CD-1 nude OVX mice. Adhesion was viewed and quan-
tified 5, 7, and 9.5 hours after insertion. (A) Color-coded fluorescent
images acquired by the IVIS 100 system of equally excised peritonea
(overlaid on a grayscale photograph). The single upper peritoneum in
each image represents fluorescence background from a naive
mouse. (B) Microscopy of equally excised peritonea. Left, H&E stain-
ing (arrows, adhered spheroid). Middle and right, Fluorescent
images (bars, 0.1 mm). (C) Average number of adhered spheroids
measured in equally excised peritonea (OVX, black, n = 4; non-
OVX, white, n = 3). Small, ≤0.1 mm; large, >0.1 mm; bulk, >1
spheroid (error bars, SE; *P < .05, two-tailed, unpaired t test).
Figure 3. OVX induces HAS2 mRNA levels in the adhered spher-
oid, and the surrounding muscle. H&E staining and in situ hybrid-
ization using a HAS2-specific probe on histologic sections of the
tumor and the muscle, derived from adhered spheroids 4 days
after i.p. insertion into OVX and non-OVX mice. HAS2 mRNA ex-
pression in tumor (A–B) and muscle (C–D) of OVX mice versus tu-
mor (E–F) and muscle (G–H) of non-OVX mice (right panel, in situ
hybridization, left panel, H&E).
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and bulks of spheroids detected 9.5 hours after insertion was signifi-
cantly lower than that in nontreated spheroids and OVX mice (P <
.05; Figure 4B).
Blood Vessel Imaging within the Vicinity of the Tumor
High–molecular weight HA inhibits angiogenesis in normal tis-
sues, in the preovulatory rat follicle [17], and in tumors [18], whereas
its degradation products are known to stimulate endothelial cell pro-
liferation and promote neovascularization [19]. We thus aimed to
investigate the vasculature in the area of ovarian cancer spheroid ad-
hesion 4 days after insertion. MLS cells were cultured as multicellular
tumor spheroids the size of 0.7 mm, which were prelabeled with the
vital stain Di-D for spheroid visualization on the peritoneum, and
i.p. inserted into two groups of CD-1 nude mice: OVX − DON (n =
3), and non–OVX − DON (n = 3). Four days later, the mice were
i.v. injected with dextran-FITC for blood vessel visualization on the
peritoneum 4 minutes before sacrifice. The next two groups of CD-
1-nude mice, namely OVX + DON (n = 3) and non–OVX + DON
(n = 3), were i.p. inserted with spheroids prelabeled with 4-Di-10-
Asp. Four days later, the mice were i.v. injected with BSA-ROX. Tu-
mors were not yet visible to the naked eye, so equally cut peritonea were
washed and removed onto slides for tumor detection by fluorescence
microscopy (Figure 5A). For quantification purposes of angiogenesis,
spheroids the size of 0.7 mm were prelabeled with the vital stain
4-Di-10-Asp and i.p. inserted into four groups of CD-1 nude mice:
OVX + DON (n = 3), OVX − DON (n = 3), non–OVX + DON
(n = 3), and non–OVX − DON (n = 3). Four days later, the mice were
i.v. injected with BSA-ROX 4 minutes before sacrifice. Tumor angio-
genesis can be visualized in the close surroundings of the tumor 4 days
after spheroid inoculation in the untreated groups. Immunohisto-
chemical staining of the spheroid adhesion area using an anti–CD34
antibody revealed enhanced density of blood vessels in the DON-
treated groups (Figure 5B). Analysis of the average tumor vasculature
area percentage (Figure 5C ), the average number of blood vessels
(Figure 5D), and the average diameter of blood vessels (Figure 5E) re-
vealed significantly increased tumor angiogenesis in DON-treated
mice for both OVX and non-OVX, manifested by increased vessel den-
sity and area fraction. The diameter of blood vessels seemed to be in-
creased in DON-treated non-OVX mice, but the difference was not
statistically significant.
Discussion
HA is an important constituent of the ECM and participates in tu-
mor progression in multiple manners. In ovarian carcinoma, HA is
synthesized by HASs expressed by both tumor and stroma cells and
participates in tumor cell adhesion. Ovarian carcinoma cells express
CD44, the HA receptor, and expression of this receptor was linked
with cancer prognosis [34]. Moreover, expression was shown to be
regulated by the gonadotropic hormones LH and FSH, thereby pro-
viding a mechanism that can explain enhanced metastatic progression
in postmenopausal women [13]. HA affects physiological and tumor
angiogenesis in a complex manner. High–molecular weight HA can
prevent angiogenesis [20], whereas products of its degradation by
Hyal are proangiogenic. Remarkably, ovarian cancer cells express
and secrete active Hyal [38].
The goal of this study was to evaluate the role of gonadotropin
hormones on HA synthesis and degradation and on the metastatic
peritoneal adhesion of human epithelial ovarian carcinoma cells.
MLS cells treated in vitro with either LH or FSH showed significant
concentration- and time-dependent induction of HAS2 and HAS3
gene expression. The induction pattern suggests that both HAS2
and HAS3 genes operate as late-induced genes when stimulated with
LH or FSH. Both HAS2 and HAS3 stimulated by the LH hormone
did not show a decrease in expression levels after the peak because
the decrease most probably occurs later than 48 hours after stimula-
tion. In situ hybridization in OVX mice indicated an increase in HAS2
mRNA levels when compared with the staining in non-OVX mice,
thus establishing that gonadotropin elevation affects HAS2 expression.
In vivo, the effects of elevated gonadotropins on mesothelial adhe-
sion were evaluated on OVX mice so as to simulate menopause. The
number of MLS spheroids detected on the mesothelium of OVX mice
was significantly higher than that in non-OVX mice, suggesting that
the change in the hormonal environment due to OVX enhanced the
ability of spheroids to adhere onto the peritoneum in vivo.
Figure 4. Peritoneal adhesion is mediated by HA. CD-1 nude OVX
mice were treated with DON (i.p.; 7.5 μg/g body weight every
24 hours for 2 days). DON was added also to the spheroid culture
medium (5 μg/ml every 24 hours for 2 days). Control mice and
spheroids were not treated with DON. DON-treated and control
spheroids (0.8-1 mm in diameter) were stained with 4-Di-10-Asp
and i.p. inserted into DON-treated and control CD-1 nude OVX mice.
Adhesionwas viewedandquantified 9.5 hours after insertion. (A) Top,
color-coded fluorescent imagesof equally excisedperitonea (overlaid
on a grayscale photograph). The single upper peritoneum in each
image represents fluorescence background from a naive mouse.
Bottom, fluorescent images (Zeiss) of whole peritonea. (B) Average
number of adhered spheroids in equally excised peritonea (DON-
treated, black, n = 5; control, white, n = 3). Small, ≤0.1 mm; large,
>0.1 mm; bulk, >1 spheroid (error bars, SE; *P < .05, two-tailed,
unpaired t test).
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DON is an effective inhibitor of glucosamine synthesis. It binds
to and inactivates the aminotransferase that transfers an amino group
from glutamine to fructose-6-P, thus inhibiting the formation of
glucosamine-6-P, an intermediate product in the production of UDP-
N -acetyl glucosamine, a substrate of the HAS enzyme in the process
of HA formation [39]. HA synthesis was inhibited both in spher-
oids and in OVX mice by DON. Consequently, the number of spher-
oids detected 9.5 hours after insertion was significantly lower than
that in nontreated spheroids and OVX mice, confirming that the
increased spheroid adhesion in OVX mice versus non-OVX mice is
due to hormonal regulation on the HAS enzyme. These data imply
that inhibition of HAS activity by DON was sufficient for decreas-
ing peritoneal adhesion of ovarian carcinoma spheroids in vivo, de-
spite the presence of additional adhesion pathways and despite the
DON-treated spheroids being slightly larger than the untreated ones,
thus underscoring the contribution of HA synthesis to ovarian car-
cinoma metastasis.
Peritoneal dissemination of ovarian carcinoma is mediated by
CD44-HA dependent adhesion of ovarian cancer cells. We have pre-
viously reported that this process is hormonally regulated by exposure
to the gonadotropins LH and FSH, which induce the expression of
CD44 and increase adhesion of cells ontoHA aswell [11]. Furthermore,
Figure 5. Angiogenesis near adhered spheroids. Spheroids of 0.7 mm were stained with a lipophilic tracer and i.p. inserted into four
groups of CD-1 nude mice: OVX + DON, OVX − DON, non–OVX + DON, and non–OVX − DON. Four days later, a macromolecular
fluorescent probe was i.v. injected 4 minutes before mice sacrifice. (A) Fluorescent images of adhered spheroids and blood vessels.
Green, adhered spheroid; red, blood vessels. Spheroids from OVX and non-OVX mice treated with DON were stained with 4-Di-10-Asp
and i.v. injected with BSA-ROX. Spheroids from OVX and non-OVX mice not treated with DON were stained with Di-D and i.v. injected
with dextran-FITC. (B) Immunohistochemical CD34 staining. Spheroids from all four groups were stained with 4-Di-10-Asp and i.v. in-
jected with BSA-ROX. (C) Blood vessel density (area percentage) of tumor vasculature in immunohistochemical CD34 staining slides
(error bars, SE; *P < .05, two-tailed, unpaired t test). (D) Blood vessel density (number/mm2) in immunohistochemical CD34 staining
slides (error bars, SE; *P < .05, two-tailed, unpaired t test). (E) Average diameter (μm) of blood vessels in immunohistochemical CD34
staining slides.
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we have reported that LH and FSH induce the expression of both
VEGF [3], which promotes angiogenesis, and the αV-integrin [11],
which affects HA-independent tumor adhesion and metastasis.
Thus, these current results of the positive gonadotropin affect both
HAS levels and the adhesion process and reinforce our hypothesis
in which the changes in the hormonal surroundings that accom-
pany menopause may lead to increased implantation of ovarian
cancer cells or spheroids on the mesothelial cell layer lining the peri-
toneal cavity.
HA coating of cells was reported to regulate modular cell adhesion
[26]. According to this scheme, HA-coated cells are repelled from
HA surfaces, whereas slight HA coating along with the CD44 HA
receptor expression will increase adhesion to these surfaces. Accord-
ingly, increased expression of HAS and elevated synthesis of HA by
the tumor cells should have reduced peritoneal adhesion, whereas
down-regulation of HAS in the tumor cells should increase meta-
static spread by exposure of CD44 on the tumor cell surface.
Unexpectedly, LH and FSH treatment elevated HAS expression by
MLS ovarian carcinoma cells and, despite that, led to an increase in
peritoneal spheroid adhesion. Furthermore, adhesion remained HA-
dependent and could be suppressed by the inhibition of HA synthe-
sis. Notably, the complexity of HA-regulated adhesion includes not
only HAS genes that produce a large range of HA molecular sizes but
also Hyals expressed and secreted by the tumor cells, which degrade
high–molecular weight HA. Here, we show that MLS cells treated
in vitro with FSH and LH showed a significant concentration- and
time-dependent induction of Hyal1, whereas Hyal2 was significantly
induced after treatment with LH. The presence of high–molecular
weight HA, which inhibits angiogenesis, and the presence of low–
molecular weight HA, which promotes angiogenesis, are managed
by a balance between the expression of HASs and Hyals, which de-
termine the amount of HA and thus the rate of angiogenesis.
Here, we report that on OVX, the increased levels of LH and FSH
cause an induction in HAS gene expression, therefore elevating HA
levels. HA seems to have a dual activity in the adhesion process. Ad-
hesion occurs on high–molecular weight HA, and once adhered, tu-
mor cells use Hyal to cleave HA into low–molecular weight fragments,
thus inducing angiogenesis. As reported here, upon HA synthesis dis-
ruption by DON, the angiogenic inhibition by high–molecular weight
HA is removed, therefore enabling angiogenesis. Accordingly, anti-
CD34 staining was elevated in the DON-treated OVX and non-
OVX compared with OVX and non-OVX mice alone. Conversely,
functional vessel density in the close vicinity of the adhered spheroids
onto the peritonea, detected by intravenously administered dextran-
FITC and BSA-ROX, was reduced in DON-treated OVX and non-
OVX mice.
Ovarian carcinoma, the most lethal gynecologic malignancy, origi-
nates predominantly from the outer epithelium of the ovary [40].
Epidemiological evidence links transformation with ovulation [41].
Thus, interruption of menstruation provides a protective effect inde-
pendently of whether such interruption was achieved through preg-
nancy, oral contraceptives, or breast-feeding [42]. Nevertheless, the
disease is more prevalent in older patients, and its progress and ag-
gressiveness in relation to other types of cancer is significantly more
severe in postmenopausal women. Hence, prolonged tumor dor-
mancy seems to be an integral part of ovarian cancer etiology, where
ovarian transformation occurs during ovulation, but the microtumors
can remain dormant for a few decades. The hormonal effects re-
ported here on HAS and on adhesion, and the complexity associated
with the dual conflicting role of HA on adhesion and angiogenesis,
provide further evidence for hormonally regulated changes in the tu-
mor microenvironment, contributing to the increased aggressiveness
of ovarian cancer observed during menopause. The clinical impact
of this pathway remains to be evaluated.
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